Antinuclear Antibody Market size is estimated at $1.3 billion in 2020, projected to grow at a CAGR of 12.3% during the forecast period 2021-2026. The Antinuclear Antibody (ANA) is a class of auto antibodies produced by a person's immune system. Antinuclear antibody testing is majorly utilized to understand the auto-immune conditions including Systemic lupus erythematosus and rheumatoid arthritis. The ANA blood test is just one component of a doctor's autoimmune disease diagnosis, which also includes a list of side effects, a physical exam, and other examinations. Tiredness, moderate fever, fatigue, light sensitivity, hair loss, joint and/or muscle pain, and tingling and numbness in the feet or hands are among the symptoms for which the doctor prefers the ANA examination. Based on the test type, the industry is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Indirect Immunofluorescence Assay, and Multiplex Testing. The market demand is growing due to increased awareness and the availability of a wide variety of diagnostic tools. The Antinuclear Antibody Industry is also being driven by technological advancements and increased healthcare spending. According to a study by the Foundation for Peripheral Neuropathy, Guillain-Barre Syndrome (GBS) affected 3,000-6,000 people in the United States each year in 2019. As a result, the demand for early screening for successful care is projected to increase as the target patient base grows.
Antinuclear Antibody Market Segment Analysis - By Test Type:
Based on Test Type, Indirect Immunofluorescence Assay accounted for the largest revenue market share in 2020 owing to its increased popularity as the gold standard for ANA research. Clinical preference grew as a result of the highly sensitive and fast test results compared to other techniques. Furthermore, their ability to recognize different patterns, such as nucleolar, speckled, and homogeneous, Systemic lupus erythematosus which indicate autoantibodies linked to diseases, is fueling the segment's development and is expected to drive market growth. The key factors fueling the development of the segment is its benefits including flexibility, sensitivity, lower cost over direct immunofluorescence and better amplification of the signal. Enzyme-Linked Immunosorbent Assay (ELISA) segment is anticipated to grow with the fastest CAGR of 12.8% in the forecast period 2021-2026. An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of blood test for detection and measurement of antibodies. It can also be used to identify any antibodies linked to an infectious disease, as antibodies are proteins produced by the body in reaction to harmful substances known as antigens. The total cost of research was decreased owing to lower labor costs for performing the test and operating the systems with highly automated systems. During the forecast period, their higher specificity in the results compared to IFA are also driving the Antinuclear Antibody Industry.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=508521
Report Price: $5900 (Single User License)
Antinuclear Antibody Market Segment Analysis – Disease Indication:
Based on Disease Indication, Rheumatoid Arthritis accounted for the largest revenue market share in 2020 owing to the growth in elderly population who are suffering from rheumatoid arthritis around the world. Rheumatoid Arthritis is basically a inflammatory ailment which affects the eyes, skin, lungs, blood vessels and heart. When a patient's immune system attacks its own body's tissues, this disease develops. Arthritis affects about one out of every three people aged 18 to 64, according to the Arthritis Foundation. It mostly affects the lining of joints, causing a painful swelling that leads to bone deterioration, joint deformity, and other complications, which for instance can be treated with better medications Glucocorticoids (GC) and are often used in acute disease flares, either orally or as intraarticular injections, Immunofluorescence Assay to relieve pain and swelling quickly while also controlling inflammation, resulting in Antinuclear Antibody Industry growth. Systemic Lupus Erythematosus is projected to witness the fastest CAGR of 12.9% during the forecast period 2021-2026. Systemic lupus erythematosus (SLE) is the chronic inflammatory disorder which impacts connective tissues including the lining of blood vessels and cartilage, that facilitates flexibility and strength to different body structures. According to the Lupus Foundation of America, lupus affects about 1.5 million people in the United States and 5 million people globally. According to estimates, 16,000 new cases of lupus are diagnosed per year. Lupus mostly affects women of childbearing age. Children, adolescents, and men, on the other hand, may develop lupus. The majority of people with lupus develop the condition between the ages of 15 and 44, thereby, driving the segment growth.
Antinuclear Antibody Market Segment Analysis - By Geography:
Based on Geography, North America Antinuclear Antibody Market accounted for the 36% revenue share in 2020 attributed to a number of factors, including an aging population that is more susceptible to infections due to reduced immunity, Systemic lupus erythematosus resulting in a high demand for early detection and successful care. According to a study published by the Centers for Disease Control and Prevention (CDC) in December 2019, GBS can affect people of any age group, but the prevalence of GBS is increasing in people over 65, necessitating a large demand due to the large geriatric population in the United States.
The major players are working on modern Antinuclear Antibody systems that are technologically advanced like Immunofluorescence Assay test type is accelerating Antinuclear Antibody Industry expansion across the region. Asia-Pacific is predicted to be the fastest growing region during the forecast period 2021- 2026 owing towards presence of a large elderly population, increasing disposable income, and rising awareness about these procedures also owing to differing regulatory factors, the market is highly diverse, resulting in differences in product availability across region.
Antinuclear Antibody Market Drivers
The Increasing Prevalence Of Autoimmune Diseases:
Antibodies help to protect the body by boosting the immune system. Antinuclear antibodies that are detected in a body indicates that the body has an autoimmune ailment. Autoimmune ailments affect around 23.5 million Americans, according to the National Institutes of Health. In addition, according to Connect Immune Research, the costs of only three autoimmune disorders, namely type 1 diabetes, rheumatoid arthritis, Systemic lupus erythematosus and multiple sclerosis, total more than £13 billion a year in the United Kingdom aiding growth towards the Antinuclear Antibody Industry. The market is also said to be driven by biomarker discovery and laboratory automation. Biomarkers are helpful in determining the type of disease, its development, and other factors. As a result, they are useful in the development of autoimmune disease studies. A variety of samples are now being used in their experiments owing to the increase in autoimmune disorders like Systemic lupus erythematosus. As a result, laboratory automation is important for handling these samples accurately and efficiently. Furthermore, a sudden outbreak of Covid-19 has prompted the government to take proactive antibody testing steps like Immunofluorescence Assay. Covid-19 test kits were delivered to both government and private testing laboratories in India in March 2020 by Indian company MyLab and German firm Altona Diagnostics. Antibody testing also has the benefit of being able to provide results in under 30 minutes, boosting the Antinuclear Antibody Industry's development.
Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=508521
Antinuclear Antibody Market Challenges
Dearth of Skilled Professional:
The Antinuclear Antibody Market is projected to be hampered by the constant rise in patient numbers, as well as the number of tests conducted with upgraded equipment, has made it difficult to find qualified clinicians who can conduct these tests. To a shortage of staff in the research units, the increasing amount of tests conducted cannot be met. According to the Bureau of Labor Statistics, the demand for lab jobs in the United States has increased by 13% in the last year. As a result, a shortage of qualified professionals disrupts the smooth operation of antibody testing and acts as a hindrance to its market development.
Antinuclear Antibody Market Landscape:
The Antinuclear Antibody Market's main strategies include product launches, mergers and acquisitions, joint ventures, and regional expansion. Antinuclear Antibody Market top 10 companies are Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Antibodies, Inc., Inova Diagnostics, Zeus Scientific, Inc., Alere Inc., Bio-Rad Laboratories, Inc., ERBA Diagnostics, Inc., Trinity Biotech plc. and Becton Dickinson and Company.
Acquisitions/Product Launches:
In October, 2019, Becton Dickinson & Company launched BD Intevi 1mL, a two-step disposable autoinjector. It is a device which combines a pre-fillable syringe and an autoinjector in one integrated system. The BD Intevia 1mL's architecture allows the pharmaceutical industry to use it for a wide range of drugs without having to change the device components. Combination products that are optimized can help to prevent problems caused by poorly integrated systems.
Key Takeaways
Antinuclear antibody (ANA) market growth is being driven by technological advances, adoption of new techniques, and the prevalence of various autoimmune diseases.
Geographically, North America Antinuclear Antibody Market held the largest revenue share of 36% in 2020 owing to the involvement of potential players who are developing innovative products, advances in medical device technology, high investments in R&D and support of government. In the final report, the scope of the Antinuclear Antibody Market for various regions will be given.
The Antinuclear Antibody Industry is expanding owing to enhanced R&D efforts by companies to develop quick, cost-effective, and new technology-based Antinuclear Antibody for the treatment of Rheumatoid Arthritis.
Infections caused by the Epstein–Barr virus, Campylobacter jejuni, and other bacteria are also expected to push the Antinuclear Antibody industry.
Related Reports :
A. Medical Devices Reimbursement Market
https://www.industryarc.com/Report/19500/medical-devices-reimbursement-market.html
B. Antibody Production Market
https://www.industryarc.com/Research/Antibody-Production-Market-Research-504143
For more Lifesciences and Healthcare Market reports, please click here
